Gene: EPB41L4B

54566
CG1|EHM2
erythrocyte membrane protein band 4.1 like 4B
protein-coding
9q31.3
Ensembl:ENSG00000095203 MIM:610340 Vega:OTTHUMG00000020470 UniprotKB:Q9H329
NC_000009.12
SNP Mapped
2   ANCO-SNPs
ND
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.281e-1 (AD)  2.451e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs12684047chr9:109210391 (GRCh38.p7)T>Anicotine dependenceSNV(Single Nucleotide Variation)
rs10759332chr9:109171981 (GRCh38.p7)A>Gnicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ST8SIA30.948
GABRB30.944
SHANK20.944
FRRS1L0.944
MYT1L0.942
CAMKV0.941
ADD20.941
FGF140.937
SLC12A50.937
MAL20.936

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CSAG1-0.56
SNHG18-0.556
MYL3-0.551
RAI14-0.544
CNN2-0.542
RUNX3-0.527
TFPI2-0.518
RAB13-0.517
HEY2-0.516
REST-0.515

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of EPB41L4B mRNA"27291303
C0065512-amino-2-methyl-1-propanol2-amino-2-methyl-1-propanol results in decreased expression of EPB41L4B mRNA25088246
C4727913-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid results in increased expression of EPB41L4B mRNA16788091
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L4B mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L4B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L4B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L4B mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of EPB41L4B mRNA21420995|2906747
D016604Aflatoxin B1Aflatoxin B1 affects the expression of EPB41L4B protein20106945
C006632arsenic trioxidearsenic trioxide results in increased expression of EPB41L4B mRNA22521957
D004958Estradiol[Estradiol co-treated with Progesterone] results in increased expression of EPB41L4B mRNA20660070
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EPB41L4B mRNA28628672
C006780bisphenol Abisphenol A results in decreased expression of EPB41L4B mRNA25181051
C054133casticincasticin results in decreased expression of EPB41L4B mRNA28444820
D003300CopperCopper deficiency results in increased expression of EPB41L4B mRNA26033743
D019327Copper SulfateCopper Sulfate results in decreased expression of EPB41L4B mRNA19549813
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EPB41L4B mRNA28628672
D019422Dietary SucroseDietary Sucrose results in increased expression of EPB41L4B mRNA26033743
D002117CalcitriolCalcitriol results in increased expression of EPB41L4B mRNA26485663
C118739entinostatentinostat results in increased expression of EPB41L4B mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L4B mRNA"27188386
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPB41L4B mRNA22079256
D004997Ethinyl Estradiol[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of EPB41L4B mRNA17942748
D005485FlutamideFlutamide results in decreased expression of EPB41L4B mRNA24136188
D017313FenretinideFenretinide results in increased expression of EPB41L4B mRNA28973697
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EPB41L4B mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EPB41L4B mRNA28628672
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of EPB41L4B mRNA24796395
D007854LeadLead affects the expression of EPB41L4B mRNA28903495
C045463leflunomideleflunomide results in increased expression of EPB41L4B mRNA28988120
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of EPB41L4B mRNA23103053
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of EPB41L4B mRNA23649840
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of EPB41L4B mRNA"20188158
C523799MRK 003EPB41L4B results in decreased susceptibility to MRK 00319903844
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of EPB41L4B mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of EPB41L4B mRNA"25554681
C051752nefazodonenefazodone results in decreased expression of EPB41L4B mRNA24136188
D009532NickelNickel results in decreased expression of EPB41L4B mRNA24768652
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in increased expression of EPB41L4B mRNA25729387
D010656PhenylephrinePhenylephrine results in increased expression of EPB41L4B mRNA18158353
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPB41L4B mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of EPB41L4B mRNA22079256
D011374Progesterone[Estradiol co-treated with Progesterone] results in increased expression of EPB41L4B mRNA20660070
D011374ProgesteroneProgesterone results in decreased expression of EPB41L4B mRNA22238285
D012643SeleniumSelenium results in decreased expression of EPB41L4B mRNA19244175
D012906SmokeSmoke results in decreased expression of EPB41L4B mRNA21095227
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of EPB41L4B mRNA20106945
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of EPB41L4B mRNA17942748
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of EPB41L4B mRNA19770486
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in increased expression of EPB41L4B mRNA25729387
C012589trichostatin Atrichostatin A results in increased expression of EPB41L4B mRNA24935251
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of EPB41L4B mRNA"26179874
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L4B mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased methylation of EPB41L4B gene29154799
D014635Valproic AcidValproic Acid results in increased expression of EPB41L4B mRNA23179753|2438349
D014635Valproic AcidValproic Acid affects the expression of EPB41L4B mRNA17292431
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of EPB41L4B gene25560391
C029297vinylidene chloridevinylidene chloride results in decreased expression of EPB41L4B mRNA26682919

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005200structural constituent of cytoskeleton-TAS10783258  
GO:0008092cytoskeletal protein binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0010628positive regulation of gene expression-IMP23664528  
GO:0010837regulation of keratinocyte proliferationNOTIMP23664528  
GO:0031032actomyosin structure organization-IBA21873635  
GO:0031032actomyosin structure organization-IDA22006950  
GO:0042060wound healing-IDA23664528  
GO:0045785positive regulation of cell adhesion-IMP23664528  
GO:0051549positive regulation of keratinocyte migration-IMP23664528  
GO ID GO Term Qualifier Evidence PubMed
GO:0005737cytoplasm-IDA23664528  
GO:0005829cytosol-IDA-  
GO:0005856cytoskeleton-IBA21873635  
GO:0005886plasma membrane-IDA-  
GO:0005923bicellular tight junction-IEA-  
GO:0045177apical part of cell-IDA22006950  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal